文献速递核素与放射性配体治疗放射性药物与辐射防护肿瘤 PET/CT

全身PET/CT:在药物研发中的作用?

Total Body PET/CT: A Role in Drug Development?
PubMed 文献 · Semin Nucl Med · 2024-10-10

全身PET凭借高灵敏度已进入医学中心并实现多种临床应用,但其在放射性药物临床评价中的潜力仍未充分探索。本文阐述全身PET可在放射性药物安全性评价的内照射剂量学、无创药代动力学研究及全身参数分析中发挥作用,并指出多中心定量性能协调的挑战。

要点

  • 全身PET的高灵敏度与定量准确性可满足放射性药物内照射剂量学对高质量图像的需求。
  • 全身PET可无创评估药物在各类血管中的放射性浓度,促进药代动力学研究。
  • 基于房室模型的全身参数分析有助于揭示放射性药物的药代动力学特征。

核心结论

  • 全身PET有潜力革新放射性药物的临床评价,并将在未来药物研发中发挥关键作用。

研究设计与样本

  • 本文为综述,未报告系统检索范围、纳入文献数量或研究方法。

主要发现

  • 放射性药物的安全性评价中,内照射剂量学需要高质量且定量准确的图像,全身PET可实现这一要求。
  • 当前放射性药物临床药代动力学研究仍依赖有创采集血液及其他体液,造成受试者不适且实施困难。
  • 全身PET可无创评估药物在各类血管中的放射性浓度,从而促进药代动力学研究。
  • 基于房室模型的全身参数分析有助于揭示放射性药物的药代动力学特征。
  • 涉及PET和SPECT的多中心临床研究要求不同成像设备间定量性能的协调,而全身PET与短轴视野PET扫描仪之间的差异可能增加复杂性。

关键数值与推荐

  • 迄今已有若干使用全身PET的创新放射性药物临床试验成功案例,涉及的示踪剂类型包括小分子、肽、纳米抗体、微抗体和适配体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 全身PET在放射性药物临床评价中的潜力仍未充分探索。
  • 全身PET与短轴视野PET扫描仪之间的差异可能增加多中心定量性能协调的复杂性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nowadays, total body PET has already entered the medical centers and enabled various clinical applications due to its superior imaging capabilities, especially the high sensitivity. However, the potential of the total body PET in the clinical evaluation of radiopharmaceuticals remains underexplored. The development and regulatory processes for radiopharmaceuticals present unique challenges that total body PET could address. In the safety evaluation of radiopharmaceuticals, the internal radiation dosimetry demands images with high quality and quantitative accuracy, which can be achieved using the total body PET. The current clinical pharmacokinetic study for radiopharmaceuticals still relies on invasively sampling of blood and other body fluid, causing discomfort of participant and difficulty in implementation. With the total body PET, the radioactive concentration of the drug in various blood vessels can be assessed noninvasively, facilitating the pharmacokinetic study. The parametric analysis over the total body based on compartment models also sheds light on the pharmacokinetics of the radiopharmaceutical. A special requirement for multi-center clinical research involving PET and SPECT is the harmonization of the quantitative performance among different imaging equipment, and the discrepancy between the total body PET and short axial field of view PET scanners may add to the complexity. To date, there are several successful examples of clinical trials of innovative radiopharmaceuticals using the total body PET, involving different types of tracers ranging from small molecules, peptides, nanobodies, minibodies, and aptamers. In conclusion, total body PET has the potential to revolutionize the clinical evaluation of radiopharmaceuticals and will play a crucial role in future drug development.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Meng X, Kong X, Wu R, et al. Total Body PET/CT: A Role in Drug Development? Semin Nucl Med. 2024. PMID: 39389888. doi:10.1053/j.semnuclmed.2024.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。